Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
John Mascarenhas(Tisch Hospital), Ronald Hoffman(Icahn School of Medicine at Mount Sinai), Rupali Bhave(Atrium Health Wake Forest Baptist), Noushin Farnoud(Memorial Sloan Kettering Cancer Center), Aishwarya Krishnan(Memorial Sloan Kettering Cancer Center), Lonette Sandy(Icahn School of Medicine at Mount Sinai), Aaron T. Gerds(Cleveland Clinic), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Mark Heaney(Immunovaccine (Canada)), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Heidi Kosiorek(Mayo Clinic in Florida), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Juan S. Medina-Martínez(Memorial Sloan Kettering Cancer Center), Vesna Najfeld, Rona Singer Weinberg(University of North Carolina at Chapel Hill), Dimitry Berenzon(Atrium Health Wake Forest Baptist), Olatoyosi Odenike(University of Chicago), Marina Kremyanskaya(Tisch Cancer Institute), Juan Arango Ossa(Memorial Sloan Kettering Cancer Center), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Erin McGovern, Amylou C. Dueck(Mayo Clinic in Arizona), Elizabeth O. Hexner(University of Pennsylvania), Camille N. Abboud(Washington University in St. Louis), Yangyu Zhou(Memorial Sloan Kettering Cancer Center), Max F. Levine(Memorial Sloan Kettering Cancer Center)
Cited by 74
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k